THALES
23.5.2024 09:01:29 CEST | Business Wire | Press release
The Mauritius Prime Minister's Office (PMO) has entrusted the consortium led by Thales, which includes the leading Mauritian-grown IT provider Harel Mallac Technologies (HMT), with a crucial step toward developing a comprehensive National ID system to improve citizen services and bolstering identity security. This partnership sets the foundations for the next generation digital journey of Mauritius, fully aligned with the country’s 2030 digital strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523106005/en/
©Thales
This ambitious modernisation effort draws on Thales experience from 300 government projects worldwide, and ensures that field-proven technology can be associated for timely delivery and reliable project execution. It is a long-term partnership providing consistent and expert support in all key components of the identity scheme, from citizen enrolment to physical and digital ID issuance. This end-to-end approach effectively meets future evolutions as well as potential identity threats.
As part of the 10-year contract Thales is providing a powerful and modular Identity Management System to securely issue cutting-edge eID cards and its mobile companion, the Digital ID Wallet. The solution assures comprehensive trust and privacy in daily interactions between public entities and individuals. The user experience is at the core of this modernisation drive, illustrated by the wider range of new functionalities and services it brings to citizens.
The citizen’s journey starts with a frictionless enrolment process, which can be initiated online from the comfort of home to save citizens time when visiting the enrolment centre. Once enrolled, the holder will receive a new eID card which relies on the latest Thales embedded software and advanced security features, including high resolution colour photo1, to effectively combat forgery and identity theft. For more convenience, self-service kiosks will be installed at dedicated spots to enable users to update their ID cards’ information (with new address, etc) and manage the PIN code associated with the digital certificates stored in their card.
Citizens can also activate their Digital ID Wallet, a secure mobile application where they can securely store and share digital identity documents. The wallet will initially include digital versions of the identity card and will subsequently contain other official documents such as birth and marriage certificates. These may then be shared both online and in-person. Citizens will also be able to digitally sign documents with a one-time certificate as well as log in to online government services by using their digital wallet. For service providers (public administrations, banks, retailers, universities, etc…) it will be a simpler and more secure way to verify identities. Citizens’ control over their personal data is guaranteed thanks to stringent data privacy and consent management mechanisms.
Mauritius identity cards production will benefit from Thales factories’ sustainability action plan, which aims to reduce the carbon footprint by utilising 100% renewable electricity, optimising energy consumption and minimising waste. As a complement to this approach, the Mauritius project is part of Thales' offsetting program which supports sustainable initiatives2 worldwide (selected in collaboration with Climate Impact Partner) by offsetting the carbon emissions from all its travel and ID solutions.
During the official launching on 26th February 2024 of the national ID card at the Sir Harilal Vaghjee Memorial Hall, Government Centre, Port Louis, it was stated that:
“The purpose of modernising the present system with sophisticated and next generation technology is to enable new services while increasing citizen security and convenience. The next-generation ID system will lay the foundation for supporting the country's digital transformation, benefiting all stakeholders and fostering economic growth.”
“With this implementation, blending ID cards and digital identity, Mauritius fully leverages the best of both worlds, offering the optimal combination of security and ease,” says Youzec Kurp, VP Identity and Biometrics Solutions at Thales. “The new Mauritius ID system stands as one of the most advanced and marks the first implementation of a fully interoperable Digital ID Wallet in Africa, adhering to international ISO standards. This positions Mauritius amongst the pioneer countries in identity solutions worldwide.”
1 The new e-document incorporates latest generation of embedded software together with advanced physical features such as Thales Colour Laser Shield technology (high resolution colour portrait) ensuring state-of-the-art protection against counterfeiting for both blank and personalised documents, True Vision (high resolution true-colour UV picture), transparent window element with the holders’ ghost image, and Secure Surface 3D tactile features combining movement and light reflection.
2 Example of supported projects in 2023: Vichada Afforestation in Colombia, Aqua Clara Water Filters in Kenya, Renewable Energy Portfolio worldwide.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity.
It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.
Thales has close to 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested.
PLEASE VISIT
Thales Group
Digital Identity & Security
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523106005/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
